This year's flu looks particularly troublesome, but that's good new for the many companies that benefit from flu sufferers' ills. Here's a look at some of them. More
-
-
Sponsored By:
-
Sponsored By:
NVS
Big Pharma: 2012-13′s Flu Vaccine Field
Here's a look at the various big pharma stocks that could see a bump from an early start to this year's flu season. More
4 Pharmaceutical Stocks to Buy Now
The grades of four Pharmaceutical stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy"). More
4 Attractive Biopharma Stocks of All Sizes
Biopharma is a high-growth niche in a defensive sector, but you need to balance risk with reward. Here are four hot biopharma stocks of different sizes. More
4 Pharmaceutical Stocks to Buy Now
Four Pharmaceutical stocks are moving up in their overall rating this week, according to the Portfolio Grader database. Every one of these is graded an "A" ("strong buy") or "B" overall ("buy"). More
Novartis Touts Pipeline of Blockbuster Drugs
Novartis says that it could produce 14 or more top-selling new drugs over the next five years as it expands its pipeline of new medications. More
Novartis Flu Vaccine Ban: Who Wins?
Two of Novartis' flu vaccines have been banned in seven countries, but the market's reaction to the move may be a bit overdone. Here's why. More
